
Results
2
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
2 companies
argenx
Market Cap: €44.6b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€717.80
7D
6.0%
1Y
36.9%
UCB
Market Cap: €50.2b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€263.90
7D
-3.7%
1Y
93.6%